ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis

Multiple Sclerosis

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane Database Syst Rev.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G

doi: 10.1002/

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)

Mult Scler.

Lünemann JD, Diaz-Diaz J, Stankoff B, Young C, Siva A, Miller A, Lubetzki C, Wiendl H, Oreja-Guevara C

doi: 10.1177/1352458520918377.

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

COMMENTED

Multiple Sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Mult Scler J Exp Transl Clin.

Kaufmann M, Kuhle J, Puhan MA, Kamm CP, Chan A, Salmen A, Kesselring J, Calabrese P, Gobbi C, Pot C, Steinemann N, Rodgers S, von Wyl V; Swiss Multiple Sclerosis Registry (SMSR)

doi: 10.1177/2055217318814562.

RECOMMENDED

Multiple Sclerosis

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Lancet Neurol.

Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N

doi: 10.1016/S1474-4422(19)30151-6.

Multiple Sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Brain.

Correale J, Gaitán MI, Ysrraelit MC, Fiol MP

doi: 10.1093/brain/aww258.

RECOMMENDED

Multiple Sclerosis

Paediatric multiple sclerosis: a new era in diagnosis and treatment

Dev Med Child Neurol.

Duignan S, Brownlee W, Wassmer E, Hemingway C, Lim M, Ciccarelli O, Hacohen Y

doi: 10.1111/dmcn.

Multiple Sclerosis

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis

Nat Rev Neurol.

Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R

doi: 10.1038/nrneurol.2017.81.

Related content

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Vaccination Readiness in Multiple Sclerosis

Highlights from the 2019 European Congress on Treatment and Research in Multiple Sclerosis (ECTRIMS 2019)

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland

Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis

Progressive multiple sclerosis: from pathogenic mechanisms to treatment

Paediatric multiple sclerosis: a new era in diagnosis and treatment

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis